Literature DB >> 20635329

Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome.

Ekaterina Chigrinova1, Michael Mian, Marta Scandurra, Timothy C Greiner, Wing C Chan, Julie M Vose, Giorgio Inghirami, Annalisa Chiappella, Luca Baldini, Maurilio Ponzoni, Andrés J M Ferreri, Silvia Franceschetti, Gianluca Gaidano, Alessandra Tucci, Fabio Facchetti, Thierry Lazure, Olivier Lambotte, Santiago Montes-Moreno, Miguel A Piris, Josep Fr Nomdedeu, Silvia Uccella, Paola M V Rancoita, Ivo Kwee, Emanuele Zucca, Francesco Bertoni.   

Abstract

Bone marrow (BM) involvement in diffuse large B-cell lymphoma (DLBCL) can be morphologically discordant from the primary tumor. Concordant BM infiltration has been shown associated with a poorer outcome in patients treated with CHOP. In order to evaluate tumor-related factors leading to BM involvement in DLBCL, we performed an integrated analysis of i) genomic profiles obtained with a high-density genome wide SNP-based arrays ii) immunomorphological and iii) clinical data from 133 patients uniformly treated with R-CHOP. BM infiltration was found in 27 of 133 (20%) cases; and it was concordant in 18/27 (67%) cases. Concordant infiltration, but not discordant, influenced negatively OS, PFS and DFS and was associated with higher serum LDH, lower CR and higher PD rates. No association with cell of origin was found between BM+ and BM- DLBCL. As compared with BM- cases, BM+ DLBCL showed absence of 7q gain.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 20635329     DOI: 10.1002/hon.953

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  10 in total

1.  Comment on "Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial".

Authors:  Theodoros P Vassilakopoulos; John Apostolidis; Maria K Angelopoulou
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

Review 2.  Discordant bone marrow involvement in non-Hodgkin lymphoma.

Authors:  Jennifer Brudno; Tamar Tadmor; Stefania Pittaluga; Alina Nicolae; Aaron Polliack; Kieron Dunleavy
Journal:  Blood       Date:  2015-12-17       Impact factor: 22.113

3.  Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

Authors:  Z Yao; L Deng; Z Y Xu-Monette; G C Manyam; P Jain; A Tzankov; C Visco; G Bhagat; J Wang; K Dybkaer; W Tam; E D Hsi; J H van Krieken; M Ponzoni; A J M Ferreri; M B Møller; J N Winter; M A Piris; L Fayad; Y Liu; Y Song; R Z Orlowski; H Kantarjian; L J Medeiros; Y Li; J Cortes; K H Young
Journal:  Leukemia       Date:  2017-07-12       Impact factor: 11.528

Review 4.  Genetic lesions in diffuse large B-cell lymphomas.

Authors:  M Testoni; E Zucca; K H Young; F Bertoni
Journal:  Ann Oncol       Date:  2015-01-20       Impact factor: 32.976

Review 5.  Aggressive B-cell lymphomas: how many categories do we need?

Authors:  Jonathan W Said
Journal:  Mod Pathol       Date:  2012-11-16       Impact factor: 7.842

6.  Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma.

Authors:  Hyun-Young Kim; Mi-Ae Jang; Hee-Jin Kim; Seok Jin Kim; Won Seog Kim; Sun-Hee Kim
Journal:  Blood Res       Date:  2017-09-25

7.  Hemophagocytic lymphohistiocytosis as an onset of diffuse large B-cell lymphoma: A case report.

Authors:  Yueqing Cao; Lang Zou; Hao Zhou; Gan Fu; Xielan Zhao
Journal:  Oncol Lett       Date:  2022-07-05       Impact factor: 3.111

8.  Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study.

Authors:  Mihai Merzianu; Adrienne Groman; Alan Hutson; Claudiu Cotta; Russell K Brynes; Attilio Orazi; Vishnu Reddy; Julie Teruya-Feldstein; Ramila Amre; Manjula Balasubramanian; Guilherme Brandao; Sindhu Cherian; Elizabeth Courville; David Czuchlewski; Guang Fan; David Grier; Daniela Hoehn; Kedar V Inamdar; Ridas Juskevicius; Prabhjot Kaur; John Lazarchick; Michael R Lewis; Rodney R Miles; Jerome B Myers; Michel R Nasr; Hina N Qureishi; Horatiu Olteanu; Valentin G Robu; Gratian Salaru; Neerja Vajpayee; Jeffrey Vos; Ling Zhang; Shanxiang Zhang; Le Aye; Elisa Brega; James E Coad; John Grantham; Sinisa Ivelja; Robert McKenna; Kieran Sultan; Gregory Wilding; Robert Hutchison; LoAnn Peterson; Richard T Cheney
Journal:  Am J Clin Pathol       Date:  2018-10-01       Impact factor: 2.493

9.  Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement.

Authors:  Seon Kim; Hyo Kim; Hye Kang; Jin Kim; Hyeon Eom; Tae Kim; Sung-Soo Yoon; Cheolwon Suh; Dong Lee
Journal:  J Hematol Oncol       Date:  2013-10-03       Impact factor: 17.388

10.  The value of bone marrow biopsy for staging of patients with primary CNS lymphoma.

Authors:  Michelle Margold; Sabine Seidel; Thomas Kowalski; Swetlana Ladigan-Badura; Alexander Baraniskin; Roland Schroers; Anna Verena Frey; Ingo G H Schmidt-Wolf; Ulrich Herrlinger; Agnieszka Korfel; Uwe Schlegel
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 12.300

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.